Clinical chemistry最新文献_第5页

Icteric, or Not Icteric, That Is the Question.

IF 7.1 2区医学

Clinical chemistry Pub Date : 2025-03-03 DOI: 10.1093/clinchem/hvae142

Thando A Gcingca, Hamere Tadesse, Caroline E Nottingham

引用次数: 0

Cardiac Troponin I and T Ratio and Risk of Cardiovascular or Non-Cardiovascular Events in a General Population

IF 9.3 2区医学

Clinical chemistry Pub Date : 2025-02-19 DOI: 10.1093/clinchem/hvaf016

Marie de Bakker, Paul Welsh, Naveed Sattar, Bertil Lindahl, Ola Hammarsten, Torbjørn Omland, Archie Campbell, Caroline Hayward, Cathie L M Sudlow, Nicholas L Mills, Dorien M Kimenai, Kai M Eggers

{"title":"Cardiac Troponin I and T Ratio and Risk of Cardiovascular or Non-Cardiovascular Events in a General Population","authors":"Marie de Bakker, Paul Welsh, Naveed Sattar, Bertil Lindahl, Ola Hammarsten, Torbjørn Omland, Archie Campbell, Caroline Hayward, Cathie L M Sudlow, Nicholas L Mills, Dorien M Kimenai, Kai M Eggers","doi":"10.1093/clinchem/hvaf016","DOIUrl":"https://doi.org/10.1093/clinchem/hvaf016","url":null,"abstract":"Background Emerging evidence suggests that the ratio between cardiac troponin (cTn) I and T may provide information on the risk of adverse outcomes in individuals with cardiovascular disease. Whether the cTn I/T ratio provides prognostic insights in the general population is unknown. Methods The cTn I/T ratio was calculated in 8855 participants (43% female, median age 56 years) from the Generation Scotland Study where both cTnI and cTnT concentrations were above the limit of blank. Multivariable cause-specific Cox proportional hazard models were used to estimate the associations between cTn I/T ratio and the primary outcome of cardiovascular or non-cardiovascular death. Results The median cTn I/T ratio was 0.5 (25th–75th percentile, 0.3–0.8) and median follow-up was 11.4 (10.8–12.7) years. Individuals in the highest ratio tertile (≥0.64) were more likely to be male, have a higher body mass index and systolic blood pressure, and a history of cardiovascular disease. Those in the lowest ratio tertile (&lt;0.38) were more likely to be smokers or have diabetes. After adjustment for cardiovascular risk factors, the cTn I/T ratio was positively associated with cardiovascular death (per doubling increase, adjusted hazard ratio [HR] 1.16 [95% CI, 1.05–1.28]), while an inverse association was observed for non-cardiovascular death (HR 0.89 [95% CI, 0.81–0.99]). Conclusions The cTn I/T ratio is positively associated with cardiovascular death in the general population, while inversely associated with non-cardiovascular death. Future research is needed to unravel underlying mechanisms and determine whether the cTn I/T ratio provides valuable information regarding risk of cardiovascular and non-cardiovascular mortality to guide further management.","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"32 1","pages":""},"PeriodicalIF":9.3,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143443212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Direct-to-Consumer Testing: Benefits and Concerns of Commercially Accessed Laboratory Tests.

IF 7.1 2区医学

Clinical chemistry Pub Date : 2025-02-18 DOI: 10.1093/clinchem/hvaf004

Matthias Orth, Sverre Sandberg, Patti Shih

{"title":"Direct-to-Consumer Testing: Benefits and Concerns of Commercially Accessed Laboratory Tests.","authors":"Matthias Orth, Sverre Sandberg, Patti Shih","doi":"10.1093/clinchem/hvaf004","DOIUrl":"https://doi.org/10.1093/clinchem/hvaf004","url":null,"abstract":"Background: Promoting self-empowerment of patients and of healthy persons in contemporary health cultures shifts the imperative for initiating laboratory tests from the healthcare professionals (HCP) to the patients themselves.Content: Laboratory testing requested directly by patients without interaction by HCP is called DTCT (direct-to-consumer testing). DTCT is not conducted within traditional healthcare systems, and the regulations that protect the patients in healthcare are not necessarily present in DTCT. Aggressive marketing of DTCT may mislead the consumer, resulting in psychological, physical, and financial harm. The benefit of laboratory testing is dependent on being used on selected persons, with samples collected and stored appropriately, measured with an adequate technique and the test results interpreted properly. DTCT can empower patients, but consumer knowledge varies and currently, there is a lack of reliable resources for consumers to consult. In the absence of healthcare protection rules for DTCT, the concept of informing consumers concurrently with marketing DTCT by the vendors is not in place.Summary: DTCT might be advantageous over traditional testing settings in a few selected situations but has a substantial risk of medicalization of healthy persons and damaging the trust in the reliability of healthcare laboratory testing.","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":" ","pages":""},"PeriodicalIF":7.1,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Slow Progress in Developing Better Long-Term Cardiovascular Risk Assessment in Women Continues.

IF 7.1 2区医学

Clinical chemistry Pub Date : 2025-02-10 DOI: 10.1093/clinchem/hvaf003

Leslie J Donato, Kyla M Lara-Breitinger, Allan S Jaffe

引用次数: 0

Glomerular Filtration Rate (GFR) Estimation with Cystatin C—Past, Present, and Future

IF 9.3 2区医学

Clinical chemistry Pub Date : 2025-02-04 DOI: 10.1093/clinchem/hvae226

Amy B Karger, Michael G Shlipak

{"title":"Glomerular Filtration Rate (GFR) Estimation with Cystatin C—Past, Present, and Future","authors":"Amy B Karger, Michael G Shlipak","doi":"10.1093/clinchem/hvae226","DOIUrl":"https://doi.org/10.1093/clinchem/hvae226","url":null,"abstract":"Background Cystatin C is a long-established filtration marker which can be used to assess kidney function, but it has been sparingly used for clinical care due to creatinine’s role as the primary biomarker for kidney function assessment based on estimated glomerular filtration rate (eGFR). Content This review summarizes the evolution of cystatin C’s role in kidney disease assessment and highlights new guidelines promoting more widespread use. Specifically, the 2021 National Kidney Foundation and American Society of Nephrology Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease report, and the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD), recommend increased use of cystatin C as an alternative and complementary biomarker for kidney function assessment, since it does not differ by race like creatinine, correlates better with adverse outcomes compared to creatinine, and provides a more accurate eGFR when used in combination with creatinine. Summary While robust literature demonstrates improved accuracy with cystatin C-based eGFR (eGFRcys) in certain clinical subpopulations, future research is needed to better understand its performance relative to creatinine-based eGFR (eGFRcr) and measured glomerular filtration rate (mGFR) in additional diverse cohorts, and to achieve assay standardization to match the performance of creatinine assays. Additionally, cystatin C testing availability will need to be broadened from primarily reference laboratories to local laboratories, and partnerships will need to be developed between clinical stakeholders and the laboratory to promote cystatin C’s clinical use, to achieve widespread adoption of guideline-recommended eGFR equations.","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"39 1","pages":""},"PeriodicalIF":9.3,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143125104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Commentary on An Unexpectedly High IgE Level during Allergic Exploration.

IF 7.1 2区医学

Clinical chemistry Pub Date : 2025-02-03 DOI: 10.1093/clinchem/hvae175

Louis Nevejan, Xavier Bossuyt

引用次数: 0

Commentary on Hiding in Plain Sight: Protein Electrophoresis Profile Inconsistent with Patient's Diagnosis.

IF 7.1 2区医学

Clinical chemistry Pub Date : 2025-02-03 DOI: 10.1093/clinchem/hvae162

Melissa R Snyder

引用次数: 0

An Unexpectedly High IgE Level during Allergic Exploration.